TriMas (NASDAQ:TRS – Get Free Report) issued an update on its FY24 earnings guidance on Monday morning. The company provided earnings per share guidance of $1.70-1.90 for the period, compared to the consensus earnings per share estimate of $1.71. TriMas also updated its FY 2024 guidance to 1.700-1.900 EPS.
Analyst Ratings Changes
Separately, BWS Financial reiterated a “buy” rating and set a $40.00 target price on shares of TriMas in a report on Wednesday, October 9th.
Get Our Latest Stock Analysis on TRS
TriMas Stock Down 4.2 %
TriMas Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, November 12th. Shareholders of record on Tuesday, November 5th will be given a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date is Tuesday, November 5th. TriMas’s dividend payout ratio (DPR) is presently 16.33%.
About TriMas
TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace, and industrial markets worldwide. The company operates through Packaging, Aerospace, and Specialty Products segments. The Packaging segment offers dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, and flexible spouts; polymeric jar products; integrated dispensers; bag-in-box products; and consumable vascular delivery and diagnostic test components under the Rieke, Taplast, Affaba & Ferrari, Intertech, Omega, and Rapak brands.
See Also
- Five stocks we like better than TriMas
- What Does a Stock Split Mean?
- Intel: Is Now the Time to Be Brave?
- What is a Dividend King?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Short Selling: How to Short a Stock
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for TriMas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriMas and related companies with MarketBeat.com's FREE daily email newsletter.